Fundz

Citius Oncology

Cranford, New Jersey, United States · Biopharma, Biotechnology, Health Care

Citius Oncology, Inc. is a Delaware-based clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. The company specializes in the development of novel cancer treatments, including targeted therapies and immunotherapies, designed to improve the effectiveness and safety of cancer care. Citius Oncology operates primarily in the United States and

Key facts

Headquarters
Cranford, New Jersey, United States
Employees
19
Industries
Biopharma, Biotechnology, Health Care
Status
Public (CTOR)
LinkedIn
Company page

Recent activity at Citius Oncology

  • : Citius Oncology secures up to $36.5 million in debt and equity capital led by Avenue Capital, advancing LYMPHIR® commercialization efforts.
  • : SEC 8-K (8.01):
  • : SEC 8-K (5.07): On September 29, 2026, Citius Oncology, Inc. held its 2026 annual meeting of stockholders, during which stockholders elected Dr. Eugene Holuka, Robert Smith, and Carol Webb as Class II directors for a three-year term expiring in 2029. The voting results showed significant support for the nominees with over 67 million votes each for, alongside a few million withheld. Additionally, the stockholders ratified the selection of Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2026, with over 73 million shares voting in favor. This meeting and its outcomes are critical as they affect the governance and future direction of the company.
  • : SEC 8-K (5.02):
  • : SEC 8-K (8.01): On August 5, 2026, Citius Oncology, Inc. announced an update regarding the expansion of its institutional accounts ordering LYMPHIR®. This press release signals the company's efforts to enhance distribution and strengthen market presence, indicating a growing recognition of its products in the healthcare sector. The specific implications for revenue or strategic partnerships were not disclosed in the filing, but the announcement is a positive indicator for investor sentiment regarding the company's growth trajectory.
  • : SEC 8-K (8.01): On June 1, 2026, Citius Oncology, Inc. announced the presentation of clinical data at the Annual Meeting of the American Society of Clinical Oncology through a press release. This event highlights significant advancements in their clinical research and may impact the company's reputation and stock performance. The press release serves to update stakeholders on important developments in the field of oncology. A copy of the press release is attached as Exhibit 99.1.
  • : SEC 8-K (1.01): On May 5, 2026, Citius Oncology, Inc. entered into a Warrant Inducement Agreement with a warrant holder to exercise existing warrants for 12,777,778 shares of common stock at a reduced exercise price of $0.90 per share, instead of the original price of $1.09. As part of this transaction, the company issued new warrants to purchase an additional 25,555,556 shares under similar terms. This agreement is significant as it facilitates the upfront cash exercise by the warrant holder and provides the company with needed liquidity. However, the exercise is subject to a 9.99% beneficial ownership limitation, impacting the timing of share issuance. The New Warrants will expire five years after stockholder approval is obtained for the share issuance.
  • : SEC 8-K (8.01): On April 29, 2026, Citius Oncology, Inc. announced through a press release the initial shipment of its product LYMPHIR™ (denileukin diftitox-cxdl) to Europe via one of its regional distribution partners. This initiative signifies a crucial step in expanding the availability of LYMPHIR™ in European markets, enhancing Citius Oncology's global presence and potentially increasing revenue streams. The press release, attached as Exhibit 99.1, details the shipment's strategic importance and outlines the company's goals for product distribution in Europe. This event reflects the company's ongoing commitment to therapeutic innovation and market expansion in critical regions.
  • : SEC 8-K (8.01): On March 31, 2026, Citius Oncology, Inc. issued a press release announcing a commercial update regarding the U.S. launch of its product LYMPHIR™ (denileukin diftitox-cxdl). This update details the company's plans and progress in introducing this new therapeutic option to the market, which is significant in the context of its oncology portfolio. The press release serves as an important communication to shareholders and stakeholders about the company's strategic direction and potential revenue implications. The timing of this launch is particularly noteworthy as it aligns with recent advancements in the company's clinical initiatives.
  • : SEC 8-K (8.01): On March 10, 2026, Citius Oncology, Inc. reported positive topline results from a Phase 1 clinical trial conducted by University of Pittsburgh researchers. The trial assessed the efficacy of LYMPHIR™ (denileukin diftitox-cxdl) in combination with pembrolizumab (KEYTRUDA®) for treating recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies. The announcement highlights the significance of this therapy's potential in oncology, marking a strategic development for the company in this therapeutic area. A press release detailing these results is attached as Exhibit 99.1.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Citius Oncology funding history

DateRoundAmount
May 2026Venture$36.5M
Dec 2025Funding Round$18.0M

Leadership

  • Omar Lansari, Director of Marketing
  • John Westman, Vice President Project Management
  • Leonard Mazur, Chief Executive Officer

Verified email and direct lines for Citius Oncology’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Companies similar to Citius Oncology

  • Lipella Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
  • Abivax · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
  • Pharma Two B Ltd · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
  • Vanda Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
  • Monopar Therapeutics · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics

About Citius Oncology: questions and answers

What does Citius Oncology do?

Citius Oncology, Inc. is a Delaware-based clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. The company specializes in the development of novel cancer treatments, including targeted therapies and immunotherapies, designed to improve the effectiveness and safety of cancer care. Citius Oncology operates primarily in the United States and

Where is Citius Oncology headquartered?

Citius Oncology is headquartered in Cranford, New Jersey, United States.

How many employees does Citius Oncology have?

Citius Oncology has about 19 employees.

Has Citius Oncology raised funding?

Yes. Fundz has recorded 2 funding events for Citius Oncology. The most recent, $36.5M, was in May 2026.

Who leads Citius Oncology?

John Westman is a Vice President Project Management at Citius Oncology.

What is the latest news on Citius Oncology?

On May 6, 2026, Citius Oncology secures up to $36.5 million in debt and equity capital led by Avenue Capital, advancing LYMPHIR® commercialization efforts.

Is Citius Oncology a public company?

Yes. Citius Oncology is publicly traded under the ticker CTOR.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Citius Oncology across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.